Ionis Pharmaceuticals Overview
- Status
- Public
- Employees
- 660

- Stock Symbol
- IONS

- Investments
- 19
- Share Price
- $36.86
- (As of Wednesday Closing)
Ionis Pharmaceuticals General Information
Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Contact Information
- 2855 Gazelle Court
- Carlsbad, CA 92010
- United States
Ionis Pharmaceuticals Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$36.86 | $37.11 | $25.04 - $44.42 | $5.26B | 142M | 1.08M | -$0.02 |
Ionis Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 4,384,227 | 3,616,659 | 6,620,295 | 7,112,637 |
Revenue | 840,768 | 810,456 | 729,264 | 1,122,599 |
EBITDA | 18,810 | (5,288) | (111,192) | 367,200 |
Net Income | (3,893) | (28,597) | (444,263) | 278,143 |
Total Assets | 2,519,092 | 2,611,690 | 2,389,755 | 3,233,112 |
Total Debt | 1,222,220 | 1,251,050 | 939,639 | 787,526 |
Ionis Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Ionis Pharmaceuticals‘s full profile, request access.
Request a free trialIonis Pharmaceuticals Comparisons
Industry
00000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialIonis Pharmaceuticals Competitors (45)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.00 | 00000000000 | 00.00 |
000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
Ionis Pharmaceuticals Patents
Ionis Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210139906-A1 | Compounds and methods for reducing spdef expression | Pending | 08-Nov-2019 | 000000000 | |
US-20210038629-A1 | Compounds and methods for modulating gfap | Pending | 26-Jul-2019 | 00000000000 | |
US-20210277397-A1 | Compounds and methods for modulating ube3a-ats | Pending | 29-Mar-2019 | 0000000000 | |
AU-2020253821-A1 | Compounds and methods for modulating ube3a-ats | Pending | 29-Mar-2019 | 0000000000 | |
CA-3135180-A1 | Compounds and methods for modulating ube3a-ats | Pending | 29-Mar-2019 | C12N15/113 |
Ionis Pharmaceuticals Executive Team (21)
Ionis Pharmaceuticals Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
000000 0000 | Self | Board Member | 000 0000 |
0. 00000000 000 | Ionis Pharmaceuticals | Board Member & Executive | 000 0000 |
00000 00000 00.0 | Ionis Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
000000000 0000 00 | Self | Board Member | 000 0000 |
0000 000000 | Self | Board Member | 000 0000 |
Ionis Pharmaceuticals Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialIonis Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Ionis Pharmaceuticals‘s full profile, request access.
Request a free trialIonis Pharmaceuticals Investments & Acquisitions (19)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000 000000000 | 23-Nov-2021 | 00000 0000 | 000.00 | Biotechnology | |
00000 0000000 | 12-Oct-2020 | 0000000000 | 00000 | Biotechnology | 00000 000 |
00000000 | 24-Dec-2019 | 00000 0000 | 0000 | Biotechnology | |
00000000 | 10-Nov-2017 | 00000 0000 | Drug Discovery | 00000 000 | |
YourBio Health | 06-Sep-2017 | Later Stage VC | 00.00 | Other Devices and Supplies | 0. 000000 |
Ionis Pharmaceuticals Exits (10)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
0000000 0000000000 | 04-Oct-2012 | 000 | 0000 | Completed |
|
000000 00000000000 | 12-Nov-2009 | 00000 00000 00 | 0000 | Completed |
|
0000000 0000000000 | 04-Mar-2009 | 00000 00000 00 | 0000 | Completed |
|
000 000000000000 | 09-Feb-2009 | 0000 | 00.00 | Completed |
|
ICO Therapeutics | 31-Dec-2007 | Early Stage VC | 0000 | Completed |